| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2025 ( Subtotal = -$162,430 ) |
| | 2025 | 2024 | MONASH UNIVERSITY | WELLINGTON RD | CLAYTON | | | | AUS | R01EB031519 | Development of 18F PET radiotracers for M2 microglia as diagnostics for multiplesclerosis pathogenesis | 000 | 2 | NIH | 12/18/2024 | $0 |
| | 2025 | 2021 | MONASH UNIVERSITY | WELLINGTON RD | CLAYTON | | | | AUS | R01AI132154 | Targeting the Urgent Need for New Antibiotics against Gram-negative ‘Superbugs’ | 000 | 5 | NIH | 10/1/2024 | -$162,430 |
|
| Issue Date FY: 2024 ( Subtotal = $496,783 ) |
| | 2024 | 2024 | MONASH UNIVERSITY | WELLINGTON RD | CLAYTON | | | | AUS | R01MH132920 | Multimodal Neuroimaging Predictors of Non-Suicidal Self-Injury in the ABCD Study | 001 | 2 | NIH | 8/28/2024 | $281,727 |
| | 2024 | 2024 | MONASH UNIVERSITY | WELLINGTON RD | CLAYTON | | | | AUS | R01EB031519 | Development of 18F PET radiotracers for M2 microglia as diagnostics for multiplesclerosis pathogenesis | 000 | 2 | NIH | 8/29/2024 | $215,056 |
| | 2024 | 2021 | MONASH UNIVERSITY | WELLINGTON RD | CLAYTON | | | | AUS | R01AI132154 | Targeting the Urgent Need for New Antibiotics against Gram-negative ‘Superbugs’ | 000 | 5 | NIH | 4/23/2024 | $0 |
|
| Issue Date FY: 2023 ( Subtotal = -$33,998 ) |
| | 2023 | 2022 | MONASH UNIVERSITY | WELLINGTON RD | CLAYTON | VIC | | | AUS | R01EB031519 | Development of 18F PET radiotracers for M2 microglia as diagnostics for multiplesclerosis pathogenesis | 001 | 1 | NIH | 8/21/2023 | -$33,998 |
| | 2023 | 2022 | MONASH UNIVERSITY | WELLINGTON RD | CLAYTON | VIC | | | AUS | R01EB031519 | Development of 18F PET radiotracers for M2 microglia as diagnostics for multiplesclerosis pathogenesis | 000 | 1 | NIH | 10/26/2022 | $0 |
| | 2023 | 2020 | MONASH UNIVERSITY | WELLINGTON RD | CLAYTON | VIC | | | AUS | R01EY026890 | Randomized controlled trial of the effect of low dose aspirin on the course of age-related macular degeneration | 000 | 5 | NIH | 4/5/2023 | $0 |
|
| Issue Date FY: 2022 ( Subtotal = $472,757 ) |
| | 2022 | 2022 | MONASH UNIVERSITY | WELLINGTON RD | CLAYTON | VIC | | | AUS | R21AI156766 | Towards the Translation of Synergistic Phage-Polymyxin Combination Therapy against Pandrug-resistant Klebsiella pneumoniae: A Systems Approach | 001 | 2 | NIH | 7/21/2022 | $137,249 |
| | 2022 | 2022 | MONASH UNIVERSITY | WELLINGTON RD | CLAYTON | VIC | | | AUS | R21AI156766 | Towards the Translation of Synergistic Phage-Polymyxin Combination Therapy against Pandrug-resistant Klebsiella pneumoniae: A Systems Approach | 002 | 2 | NIH | 8/8/2022 | -$137,249 |
| | 2022 | 2022 | MONASH UNIVERSITY | WELLINGTON RD | CLAYTON | VIC | | | AUS | R01EB031519 | Development of 18F PET radiotracers for M2 microglia as diagnostics for multiplesclerosis pathogenesis | 000 | 1 | NIH | 9/14/2022 | $322,158 |
| | 2022 | 2022 | MONASH UNIVERSITY | WELLINGTON RD | CLAYTON | VIC | | | AUS | R21AI156766 | Towards the Translation of Synergistic Phage-Polymyxin Combination Therapy against Pandrug-resistant Klebsiella pneumoniae: A Systems Approach | 002 | 2 | NIH | 8/8/2022 | $137,249 |
| | 2022 | 2021 | MONASH UNIVERSITY | WELLINGTON RD | CLAYTON | VIC | | | AUS | R21AI156766 | Towards the Translation of Synergistic Phage-Polymyxin Combination Therapy against Pandrug-resistant Klebsiella pneumoniae: A Systems Approach | 000 | 1 | NIH | 11/4/2021 | $13,350 |
| | 2022 | 2019 | MONASH UNIVERSITY | WELLINGTON RD | CLAYTON | VIC | | | AUS | R03AG054950 | From a Venom to a Potential Treatment for Alzheimer's Disease | 000 | 2 | NIH | 4/19/2022 | $0 |
|
| Issue Date FY: 2021 ( Subtotal = $1,037,850 ) |
| | 2021 | 2021 | MONASH UNIVERSITY | WELLINGTON RD | CLAYTON | VIC | | | AUS | R21AI156766 | Towards the Translation of Synergistic Phage-Polymyxin Combination Therapy against Pandrug-resistant Klebsiella pneumoniae: A Systems Approach | 000 | 1 | NIH | 8/16/2021 | $197,381 |
| | 2021 | 2021 | MONASH UNIVERSITY | WELLINGTON RD | CLAYTON | VIC | | | AUS | R01AI132154 | Targeting the Urgent Need for New Antibiotics against Gram-negative ‘Superbugs’ | 000 | 5 | NIH | 8/9/2021 | $840,469 |
| | 2021 | 2019 | MONASH UNIVERSITY | WELLINGTON RD | CLAYTON | VIC | | | AUS | R03AG054950 | From a Venom to a Potential Treatment for Alzheimer's Disease | 000 | 2 | NIH | 4/8/2021 | $0 |
|
| Issue Date FY: 2020 ( Subtotal = $1,086,738 ) |
| | 2020 | 2020 | MONASH UNIVERSITY | WELLINGTON RD | CLAYTON | VIC | 3168 | | AUS | R01AI132154 | Targeting the Urgent Need for New Antibiotics against Gram-negative ‘Superbugs’ | 000 | 4 | NIH | 7/17/2020 | $840,469 |
| | 2020 | 2020 | MONASH UNIVERSITY | WELLINGTON RD | CLAYTON | VIC | 3168 | | AUS | R01EY026890 | Randomized controlled trial of the effect of low dose aspirin on the course of age-related macular degeneration | 000 | 5 | NIH | 8/6/2020 | $246,269 |
|
| Issue Date FY: 2019 ( Subtotal = $1,198,915 ) |
| | 2019 | 2019 | MONASH UNIVERSITY | WELLINGTON RD | CLAYTON | VIC | 3168 | | AUS | R01EY026890 | Randomized controlled trial of the effect of low dose aspirin on the course of age-related macular degeneration | 000 | 4 | NIH | 8/6/2019 | $350,790 |
| | 2019 | 2019 | MONASH UNIVERSITY | WELLINGTON RD | CLAYTON | VIC | 3168 | | AUS | R01AI132154 | Targeting the Urgent Need for New Antibiotics against Gram-negative ‘Superbugs’ | 000 | 3 | NIH | 7/25/2019 | $794,600 |
| | 2019 | 2019 | MONASH UNIVERSITY | WELLINGTON RD | CLAYTON | VIC | 3168 | | AUS | R03AG054950 | From a Venom to a Potential Treatment for Alzheimer's Disease | 000 | 2 | NIH | 5/21/2019 | $53,525 |
| | 2019 | 2018 | MONASH UNIVERSITY | WELLINGTON RD | CLAYTON | VIC | 3168 | | AUS | R01AI111965 | New Tricks for 'Old' Drugs: PK/PD of Polymyxin Nonantibiotic Combinations | 000 | 5 | NIH | 8/27/2019 | $0 |
|
| Issue Date FY: 2018 ( Subtotal = $2,012,671 ) |
| | 2018 | 2018 | MONASH UNIVERSITY | WELLINGTON RD | CLAYTON | VIC | 3168 | | AUS | R01AI111965 | New Tricks for 'Old' Drugs: PK/PD of Polymyxin Nonantibiotic Combinations | 000 | 5 | NIH | 5/4/2018 | $819,605 |
| | 2018 | 2018 | MONASH UNIVERSITY | WELLINGTON RD | CLAYTON | VIC | 3168 | | AUS | R01EY026890 | Randomized controlled trial of the effect of low dose aspirin on the course of age-related macular degeneration | 000 | 3 | NIH | 8/21/2018 | $349,854 |
| | 2018 | 2018 | MONASH UNIVERSITY | WELLINGTON RD | CLAYTON | VIC | 3168 | | AUS | R01AI132154 | Targeting the Urgent Need for New Antibiotics against Gram-negative ‘Superbugs’ | 000 | 2 | NIH | 7/19/2018 | $793,759 |
| | 2018 | 2018 | MONASH UNIVERSITY | WELLINGTON RD | CLAYTON | VIC | 3168 | | AUS | R03AG054950 | From a Venom to a Potential Treatment for Alzheimer's Disease | 000 | 1 | NIH | 9/15/2018 | $53,559 |
| | 2018 | 2016 | MONASH UNIVERSITY | WELLINGTON RD | CLAYTON | VIC | 3168 | | AUS | R01AI098771 | Targeting superbugs: discovery and development of new broad-spectrum lipopeptides | 000 | 5 | NIH | 9/26/2018 | -$4,106 |
| | 2018 | 2016 | MONASH UNIVERSITY | WELLINGTON RD | CLAYTON | VIC | 3168 | | AUS | R01HD072848 | Facilitating The Physiological Transition at Birth In Term And Preterm Neonates | 000 | 4 | NIH | 11/3/2017 | $0 |
|
| Issue Date FY: 2017 ( Subtotal = $2,264,502 ) |
| | 2017 | 2017 | MONASH UNIVERSITY | WELLINGTON RD | CLAYTON | VIC | 3168 | | AUS | R01EY026890 | Randomized controlled trial of the effect of low dose aspirin on the course of age-related macular degeneration | 000 | 2 | NIH | 9/12/2017 | $348,949 |
| | 2017 | 2017 | MONASH UNIVERSITY | WELLINGTON RD | CLAYTON | VIC | 3168 | | AUS | R01AI111965 | New Tricks for 'Old' Drugs: PK/PD of Polymyxin Nonantibiotic Combinations | 000 | 4 | NIH | 3/22/2017 | $855,749 |
| | 2017 | 2017 | MONASH UNIVERSITY | WELLINGTON RD | CLAYTON | VIC | 3168 | | AUS | R01AI132154 | Targeting the Urgent Need for New Antibiotics against Gram-negative ‘Superbugs’ | 000 | 1 | NIH | 7/25/2017 | $1,059,804 |
|
| Issue Date FY: 2016 ( Subtotal = $2,551,481 ) |
| | 2016 | 2016 | MONASH UNIVERSITY | 1 WELLINGTON ROAD | CLAYTON | | | | AUS | R01EY026890 | Randomized controlled trial of the effect of low dose aspirin on the course of age-related macular degeneration | 000 | 1 | NIH | 9/5/2016 | $328,519 |
| | 2016 | 2016 | MONASH UNIVERSITY | 1 WELLINGTON ROAD | CLAYTON | | | | AUS | R01HD072848 | Facilitating The Physiological Transition at Birth In Term And Preterm Neonates | 000 | 4 | NIH | 6/16/2016 | $351,354 |
| | 2016 | 2016 | MONASH UNIVERSITY | 1 WELLINGTON ROAD | CLAYTON | | | | AUS | R01AI098771 | Targeting superbugs: discovery and development of new broad-spectrum lipopeptides | 000 | 5 | NIH | 4/28/2016 | $996,973 |
| | 2016 | 2016 | MONASH UNIVERSITY | 1 WELLINGTON ROAD | CLAYTON | | | | AUS | R01AI111965 | New Tricks for 'Old' Drugs: PK/PD of Polymyxin Nonantibiotic Combinations | 000 | 3 | NIH | 3/17/2016 | $874,635 |
|
| Issue Date FY: 2015 ( Subtotal = $2,090,833 ) (Continued on the next page) |
| | 2015 | 2015 | MONASH UNIVERSITY | 1 WELLINGTON ROAD | CLAYTON | | | | AUS | R01HD072848 | Facilitating The Physiological Transition at Birth In Term And Preterm Neonates | 000 | 3 | NIH | 5/19/2015 | $358,991 |
| | 2015 | 2015 | MONASH UNIVERSITY | 1 WELLINGTON ROAD | CLAYTON | | | | AUS | R01AI111965 | New Tricks for 'Old' Drugs: PK/PD of Polymyxin Nonantibiotic Combinations | 000 | 2 | NIH | 3/18/2015 | $893,305 |
| | 2015 | 2015 | MONASH UNIVERSITY | 1 WELLINGTON ROAD | CLAYTON | | | | AUS | R01AI098771 | Targeting superbugs: discovery and development of new broad-spectrum lipopeptides | 000 | 4 | NIH | 4/23/2015 | $838,537 |
|
